BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
14 12 2020
14 12 2020
Historique:
received:
02
02
2020
revised:
23
04
2020
accepted:
11
05
2020
pubmed:
16
5
2020
medline:
29
4
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
BRCA1 methylation has been associated with homologous recombination deficiency, a biomarker of platinum sensitivity. Studies evaluating BRCA1-methylated tubal and ovarian cancer (OC) do not consistently support improved survival following platinum chemotherapy. We examine the characteristics of BRCA1-methylated OC in a meta-analysis of individual participant data. Data of 2636 participants across 15 studies were analyzed. BRCA1-methylated tumors were defined according to their original study. Associations between BRCA1 methylation and clinicopathological characteristics were evaluated. The effects of methylation on overall survival (OS) and progression-free survival (PFS) were examined using mixed-effects models. All statistical tests were 2-sided. 430 (16.3%) tumors were BRCA1-methylated. BRCA1 methylation was associated with younger age and advanced-stage, high-grade serous OC. There were no survival differences between BRCA1-methylated and non-BRCA1-methylated OC (median PFS = 20.0 vs 18.5 months, hazard ratio [HR] = 1.01, 95% CI = 0.87 to 1.16; P = .98; median OS = 46.6 vs 48.0 months, HR = 1.02, 95% CI = 0.87 to 1.18; P = .96). Where BRCA1/2 mutations were evaluated (n = 1248), BRCA1 methylation displayed no survival advantage over BRCA1/2-intact (BRCA1/2 wild-type non-BRCA1-methylated) OC. Studies used different methods to define BRCA1 methylation. Where BRCA1 methylation was determined using methylation-specific polymerase chain reaction and gel electrophoresis (n = 834), it was associated with improved survival (PFS: HR = 0.80, 95% CI = 0.66 to 0.97; P = .02; OS: HR = 0.80, 95% CI = 0.63 to 1.00; P = .05) on mixed-effects modeling. BRCA1-methylated OC displays similar clinicopathological features to BRCA1-mutated OC but is not associated with survival. Heterogeneity within BRCA1 methylation assays influences associations. Refining these assays may better identify cases with silenced BRCA1 function and improved patient outcomes.
Sections du résumé
BACKGROUND
BRCA1 methylation has been associated with homologous recombination deficiency, a biomarker of platinum sensitivity. Studies evaluating BRCA1-methylated tubal and ovarian cancer (OC) do not consistently support improved survival following platinum chemotherapy. We examine the characteristics of BRCA1-methylated OC in a meta-analysis of individual participant data.
METHODS
Data of 2636 participants across 15 studies were analyzed. BRCA1-methylated tumors were defined according to their original study. Associations between BRCA1 methylation and clinicopathological characteristics were evaluated. The effects of methylation on overall survival (OS) and progression-free survival (PFS) were examined using mixed-effects models. All statistical tests were 2-sided.
RESULTS
430 (16.3%) tumors were BRCA1-methylated. BRCA1 methylation was associated with younger age and advanced-stage, high-grade serous OC. There were no survival differences between BRCA1-methylated and non-BRCA1-methylated OC (median PFS = 20.0 vs 18.5 months, hazard ratio [HR] = 1.01, 95% CI = 0.87 to 1.16; P = .98; median OS = 46.6 vs 48.0 months, HR = 1.02, 95% CI = 0.87 to 1.18; P = .96). Where BRCA1/2 mutations were evaluated (n = 1248), BRCA1 methylation displayed no survival advantage over BRCA1/2-intact (BRCA1/2 wild-type non-BRCA1-methylated) OC. Studies used different methods to define BRCA1 methylation. Where BRCA1 methylation was determined using methylation-specific polymerase chain reaction and gel electrophoresis (n = 834), it was associated with improved survival (PFS: HR = 0.80, 95% CI = 0.66 to 0.97; P = .02; OS: HR = 0.80, 95% CI = 0.63 to 1.00; P = .05) on mixed-effects modeling.
CONCLUSION
BRCA1-methylated OC displays similar clinicopathological features to BRCA1-mutated OC but is not associated with survival. Heterogeneity within BRCA1 methylation assays influences associations. Refining these assays may better identify cases with silenced BRCA1 function and improved patient outcomes.
Identifiants
pubmed: 32413141
pii: 5837681
doi: 10.1093/jnci/djaa070
pmc: PMC7735770
doi:
Substances chimiques
BRCA1 Protein
0
BRCA1 protein, human
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1190-1203Subventions
Organisme : NCI NIH HHS
ID : P50 CA217685
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Nat Commun. 2017 Aug 22;8(1):319
pubmed: 28831036
Gynecol Oncol. 2018 Feb;148(2):281-285
pubmed: 29233532
J Biol Chem. 1997 Aug 22;272(34):20994-7
pubmed: 9261099
Br J Cancer. 2012 Nov 6;107(10):1776-82
pubmed: 23047548
Oncogene. 1999 Mar 18;18(11):1957-65
pubmed: 10208417
Oncotarget. 2017 Sep 15;8(47):83063-83074
pubmed: 29137324
JAMA. 2011 Oct 12;306(14):1557-65
pubmed: 21990299
Epigenetics. 2012 Nov;7(11):1225-9
pubmed: 23069641
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
J Gynecol Oncol. 2015 Apr;26(2):87-9
pubmed: 25872889
Oncol Lett. 2014 Apr;7(4):1088-1096
pubmed: 24944674
Sci Rep. 2014 Feb 07;4:4026
pubmed: 24504028
Front Oncol. 2019 Nov 29;9:1289
pubmed: 31850198
Cancer. 2001 Aug 15;92(4):787-95
pubmed: 11550149
J Biol Chem. 1999 Mar 26;274(13):8837-43
pubmed: 10085126
BMC Cancer. 2006 Aug 23;6:212
pubmed: 16928264
Histopathology. 2010 Sep;57(3):363-70
pubmed: 20840667
Sci Rep. 2015 Dec 08;5:17869
pubmed: 26643130
J Natl Cancer Inst. 2002 Sep 18;94(18):1396-406
pubmed: 12237285
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Oncogene. 1996 Jun 20;12(12):2507-13
pubmed: 8700509
J Clin Oncol. 2010 Aug 1;28(22):3570-6
pubmed: 20606085
Clin Cancer Res. 2016 Aug 1;22(15):3764-73
pubmed: 26957554
Breast Cancer Res. 2014 Dec 05;16(6):475
pubmed: 25475740
Target Oncol. 2020 Feb;15(1):37-46
pubmed: 31960278
Eur J Cancer. 2014 Aug;50(12):2090-8
pubmed: 24889916
J Pathol. 2004 Feb;202(2):215-23
pubmed: 14743504
Gynecol Oncol. 2012 Mar;124(3):582-8
pubmed: 22115852
Mod Pathol. 2012 May;25(5):740-50
pubmed: 22282309
Asian Pac J Cancer Prev. 2014;15(21):9479-85
pubmed: 25422243
Nat Rev Cancer. 2010 Nov;10(11):803-8
pubmed: 20944665
PLoS One. 2016 Jul 27;11(7):e0160174
pubmed: 27463681
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Clin Cancer Res. 2015 Feb 1;21(3):652-7
pubmed: 25398451
Clin Cancer Res. 2007 Dec 15;13(24):7421-31
pubmed: 18094426
Mol Oncol. 2014 May;8(3):656-68
pubmed: 24560445
BMC Cancer. 2008 Jan 22;8:17
pubmed: 18208621
Anal Cell Pathol (Amst). 2010;33(3):133-41
pubmed: 20978321
Int J Gynecol Cancer. 2011 Nov;21(8):1399-406
pubmed: 21897273
Clin Cancer Res. 2002 May;8(5):1196-202
pubmed: 12006538
Mol Oncol. 2013 Jun;7(3):567-79
pubmed: 23415752
Gynecol Oncol. 2006 Jun;101(3):403-10
pubmed: 16360812
Cancer Res. 2000 Oct 1;60(19):5329-33
pubmed: 11034065
Clin Cancer Res. 2012 Oct 15;18(20):5806-15
pubmed: 22912389
Br J Cancer. 2018 Oct;119(9):1060-1066
pubmed: 30318511
J Cancer Res Clin Oncol. 2014 Sep;140(9):1457-63
pubmed: 24825122
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
Cancer Invest. 2009 Oct;27(8):877-84
pubmed: 19548140
J Natl Cancer Inst. 2002 Jan 2;94(1):61-7
pubmed: 11773283
Bioinformatics. 2011 Nov 15;27(22):3206-8
pubmed: 21903630
Cancer Genet. 2012 Mar;205(3):94-100
pubmed: 22469508
Clin Genet. 2009 Aug;76(2):161-7
pubmed: 19656163
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
J Clin Oncol. 2010 Oct 10;28(29):e563-4; author reply e565-6
pubmed: 20679605
Cancer. 2006 Jul 15;107(2):299-308
pubmed: 16773633
Tumour Biol. 2016 Sep;37(9):12329-12337
pubmed: 27297669
Mol Med Rep. 2014 May;9(5):1844-50
pubmed: 24573411
Mol Cancer. 2009 Jul 14;8:48
pubmed: 19602291
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120